Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER)-Raebareli, Bijnor-Sisendi Road, Sarojini Nagar, Lucknow, Uttar Pradesh, 226002, India.
School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, PR1 2HE, UK.
Mol Neurobiol. 2024 Nov;61(11):8702-8738. doi: 10.1007/s12035-024-04015-9. Epub 2024 Apr 1.
Blood-brain barrier (BBB) is a distinguishing checkpoint that segregates peripheral organs from neural compartment. It protects the central nervous system from harmful ambush of antigens and pathogens. Owing to such explicit selectivity, the BBB hinders passage of various neuroprotective drug molecules that escalates into poor attainability of neuroprotective agents towards the brain. However, few molecules can surpass the BBB and gain access in the brain parenchyma by exploiting surface transporters and receptors. For successful development of brain-targeted therapy, understanding of BBB transporters and receptors is crucial. This review focuses on the transporter and receptor-based mechanistic pathway that can be manoeuvred for better comprehension of reciprocity of receptors and nanotechnological vehicle delivery. Nanotechnology has emerged as one of the expedient noninvasive approaches for brain targeting via manipulating the hurdle of the BBB. Various nanovehicles are being reported for brain-targeted delivery such as nanoparticles, nanocrystals, nanoemulsion, nanolipid carriers, liposomes and other nanovesicles. Nanotechnology-aided brain targeting can be a strategic approach to circumvent the BBB without altering the inherent nature of the BBB.
血脑屏障(BBB)是分隔外周器官和神经区室的独特关卡。它保护中枢神经系统免受抗原和病原体的有害侵袭。由于这种明显的选择性,BBB 阻碍了各种神经保护药物分子的通过,导致神经保护剂向大脑的可达性降低。然而,有少数分子可以通过利用表面转运体和受体来突破 BBB 并进入脑实质。为了成功开发脑靶向治疗,了解 BBB 转运体和受体至关重要。本综述重点介绍了基于转运体和受体的机制途径,这可以更好地理解受体的相互作用和纳米技术载体的递药。纳米技术已成为通过操纵 BBB 障碍进行脑靶向的一种便利的非侵入性方法。正在报道各种用于脑靶向递送的纳米载体,如纳米颗粒、纳米晶体、纳米乳剂、纳米脂质载体、脂质体和其他纳米载体。纳米技术辅助的脑靶向可以是一种策略性方法,可在不改变 BBB 固有性质的情况下绕过 BBB。
Mol Neurobiol. 2024-11
Expert Opin Drug Deliv. 2019-2-26
J Control Release. 2018-10-9
J Neuroimmune Pharmacol. 2016-7-23
Curr Cancer Drug Targets. 2012-3
Int J Nanomedicine. 2014-2-7
Mol Neurobiol. 2024-7
Adv Drug Deliv Rev. 2022-12
Eur J Pharm Biopharm. 2022-12
Pharmaceutics. 2022-10-11
Pharmaceutics. 2022-9-5